Richard D. Pilnik
Known title: DirectorCIK: 0001760016
Richard D. Pilnik's purchase track record
How the stock did after each of Richard D. Pilnik's open-market purchases, measured from the purchase date. Several fills within a week count as one purchase.
Purchases measured
3
of 3 since August 16, 2021
Stock higher 6 months later
33%
3 months: 67%
Median 6-month return
-8.8%
3 months: +22.5%
Beat the S&P 500
33%
median -7.1% vs. index
| Purchase | Stock | Amount | 3 months | 6 months | S&P 500, 6 mo. |
|---|---|---|---|---|---|
| 6/23/2023 | DMAC | $150K | -34.1% | -32.9% | +9.3% |
| 12/5/2022 | DMAC | $48K | +35.9% | +106.1% | +6.9% |
| 8/16/2021 | DMAC | $49K | +22.5% | -8.8% | -1.7% |
Computed by MarketWall from SEC Form 4 filings and daily closing prices (close on the purchase date to the close about 3 and 6 months later). Companies that have since delisted are not included. Past results, not investment advice.
Associated companies
Transaction History
| DMAC | ▲ Buy | Option Exercise | 24,000 | $51K | 4/7/2025 | View on chart |
| DMAC | ▲ Buy | Grant | 10,393 | $55K | 1/2/2025 | View on chart |
| DMAC | ▲ Buy | Grant | 30,357 | $85K | 1/2/2024 | View on chart |
| DMAC | ▲ Buy | Open Market | 38,363 | $150K | 6/23/2023 | View on chart |
| DMAC | ▲ Buy | Grant | 55,555 | $85K | 1/3/2023 | View on chart |
| DMAC | ▲ Buy | Open Market | 35,000 | $48K | 12/5/2022 | View on chart |
| DMAC | ▲ Buy | Grant | 23,762 | $85K | 1/3/2022 | View on chart |
| DMAC | ▲ Buy | Open Market | 2,500 | $8K | 8/16/2021 | View on chart |
| DMAC | ▲ Buy | Open Market | 12,500 | $41K | 8/16/2021 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 30, 2026
DiaMedica Shares Early Phase 2 Data for DM199 in Fetal Growth Restriction
DiaMedica Therapeutics is highlighting early Phase 2 results for its lead candidate, DM199, which targets fetal growth restriction. The company is using a webinar with key opinion leaders to discuss these findings, signaling a focus on advancing its clinical narrative. This update provides new information on the drug's potential efficacy as it moves through its development stages.
DiaMedica Shares Early Phase 2 Data for DM199 in Fetal Growth Restriction. DiaMedica Therapeutics is highlighting early Phase 2 results for its lead candidate, DM199, which targets fetal growth restriction. The company is using a webinar with key opinion leaders to discuss these findings, signaling a focus on advancing its clinical narrative. This update provides new information on the drug's potential efficacy as it moves through its development stages.